Short Interest of The Day: What’s in Catalent Incorporated (NYSE:CTLT) After Rise in Shorted Shares?

November 30, 2016 - By Marguerite Chambers
·
0 Comments

The stock of Catalent Incorporated (NYSE:CTLT) registered an increase of 5.21% in short interest. CTLT’s total short interest was 4.61M shares in November as published by FINRA. Its up 5.21% from 4.38M shares, reported previously. With 705,100 shares average volume, it will take short sellers 7 days to cover their CTLT’s short positions. The short interest to Catalent Incorporated’s float is 3.71%. About 265,342 shares traded hands. Catalent Inc (NYSE:CTLT) has declined 19.23% since April 27, 2016 and is downtrending. It has underperformed by 24.46% the S&P500.

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. The company has a market cap of $2.97 billion. The Company’s divisions include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. It has a 28.21 P/E ratio. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Insitutional Activity: The institutional sentiment increased to 2.72 in 2016 Q2. Its up 0.98, from 1.74 in 2016Q1. The ratio improved, as 23 funds sold all Catalent Inc shares owned while 38 reduced positions. 26 funds bought stakes while 80 increased positions. They now own 124.13 million shares or 1.11% less from 125.52 million shares in 2016Q1.
Loomis Sayles & Lp accumulated 1.13 million shares or 0.07% of the stock. Perkins Investment Mgmt Limited Liability Company holds 692,029 shares or 0.24% of its portfolio. Goldman Sachs reported 1.95M shares or 0.01% of all its holdings. First Mercantile Trust last reported 0.02% of its portfolio in the stock. Sei Invs has 0% invested in the company for 8 shares. Numeric Ltd Liability Corporation holds 0% of its portfolio in Catalent Inc (NYSE:CTLT) for 23,300 shares. Interest Group Incorporated accumulated 0% or 261,473 shares. Citadel Ltd Co reported 144,620 shares or 0% of all its holdings. Sg Americas Ltd Liability Corporation, a New York-based fund reported 25,322 shares. Arizona State Retirement Sys reported 45,373 shares or 0.01% of all its holdings. Citigroup has invested 0% of its portfolio in Catalent Inc (NYSE:CTLT). Moreover, Eaton Vance Mgmt has 0.01% invested in Catalent Inc (NYSE:CTLT) for 186,000 shares. Moreover, Blackrock Institutional Trust Na has 0.01% invested in Catalent Inc (NYSE:CTLT) for 3.17 million shares. York Management Glob Limited Company owns 851,500 shares or 0.49% of their US portfolio. Nuveen Asset Mngmt Ltd Com holds 45,802 shares or 0.01% of its portfolio.

Catalent Inc (NYSE:CTLT) Ratings Coverage

Out of 8 analysts covering Catalent (NYSE:CTLT), 5 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 63% are positive. Catalent has been the topic of 14 analyst reports since September 3, 2015 according to StockzIntelligence Inc. The firm earned “Mkt Perform” rating on Wednesday, December 9 by Raymond James. The firm earned “Overweight” rating on Thursday, October 20 by KeyBanc Capital Markets. The rating was downgraded by Morgan Stanley to “Ewu” on Thursday, April 21. The rating was upgraded by Wells Fargo to “Outperform” on Tuesday, June 21. The firm earned “Hold” rating on Thursday, September 29 by Jefferies. Bank of America maintained the stock with “Buy” rating in Thursday, September 3 report. The company was upgraded on Monday, June 20 by Bank of America. Deutsche Bank maintained Catalent Inc (NYSE:CTLT) on Wednesday, November 4 with “Hold” rating. The firm earned “Market Perform” rating on Tuesday, December 22 by Wells Fargo. Jefferies downgraded the stock to “Hold” rating in Thursday, September 10 report.

CTLT Company Profile

Catalent, Inc., incorporated on March 14, 2007, is a well-known provider of delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. The Company’s divisions include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels, including traditional softgel capsules (in which the shell is made from animal-derived materials), and Vegicaps and OptiShell capsules (in which the shell is made from vegetable-derived materials). The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products using its OptiMelt, OptiPact, OptiForm and Zydis technologies, other drug delivery technologies, such as prefilled syringes; blow-fill seal unit dose manufacturing, including its ADVASEPT technology; biologic cell line development, including its GPEx and SMARTag technologies; and analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for customer required patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.

More news for Catalent Inc (NYSE:CTLT) were recently published by: Streetinsider.com, which released: “Catalent (CTLT) Announces Acquisition of OTC Softgel Maker Accucaps Industries” on November 28, 2016. Businesswire.com‘s article titled: “Catalent, Inc. Appoints Uwe RÃ¶hrhoff to its Board of Directors” and published on October 31, 2016 is yet another important article.